Introduction: Psoriasis is a chronic inflammatory skin disease significantly impairing quality of life. The introduction of biologic therapies, such as bimekizumab—a monoclonal antibody targeting IL-17A and IL-17F—has revolutionized treatment outcomes. This study investigates the effectiveness of bimekizumab in a real-world setting, focusing on the predictors of Early Super Response (ESR), defined as achieving PASI 100 by week 4, and evaluates the safety profile over a 48-week follow-up period. Methods: A retrospective study was conducted on 109 psoriasis patients treated with bimekizumab at two Italian dermatology centers. Of these, 61 patients completed a 48-weeks follow-up. Baseline clinical and demographic data, PASI scores at multiple time points, and adverse events were collected. ESR predictors were analyzed using univariate and multivariate logistic regression models. Safety was assessed using Cox proportional hazards models to find predictive factors associated with the risk of adverse events (AEs). Results: At week 4, 28.4% of patients achieved PASI 100. Baseline PASI (OR: 0.93, p = 0.029), absence of nail involvement (OR: 0.12, p = 0.003), and fewer biologic failures (OR: 0.14, p = 0.038) were independently associated with ESR status. Safety analysis revealed that 15.6% of patients experienced adverse events, with asthma/allergic rhinitis significantly associated with a higher risk (HR: 6.43, p = 0.012). Candidiasis (7.3%) and eczema (4.6%) were the most common adverse events. Conclusion: Bimekizumab demonstrated significant effectiveness and an acceptable safety profile in a real-world setting. Baseline PASI, nail involvement, and prior biologic failures influenced early treatment response. Identifying predictors of ESR and adverse events can guide personalized therapeutic approaches, optimizing outcomes for psoriasis patients.

Purpose: Dupilumab, a fully human monoclonal antibody that inhibits the signaling pathways of interleukin (IL)-4 and IL-13, has demonstrated remarkable efficacy in the treatment of atopic dermatitis (AD). Dupilumab has been reported to attenuate itch and reduce several serum markers, including blood lactate dehydrogenase (LDH), blood eosinophil count, and serum total immunoglobulin E (IgE). Patients and Methods: The present study investigated retrospectively changes in clinical scores and serum biomarker from 175 adults with moderate-to-severe AD treated with dupilumab. Clinical manifestations were assessed using eczema area and severity index (EASI) and visual analogue scale (VAS) for itch at baseline and subsequently at 16-week intervals up to a duration of 48 weeks. Total IgE, LDH and blood eosinophil count were also collected. Results: The dupilumab treatment significantly improved EASI and VAS scores and decreased serum levels of IgE, LDH, and total eosinophil count. The EASI scores were positively correlated with VAS for itch at all recorded time points, whereas serum biomarkers did not exhibit a strong correlation with EASI scores. Conclusion: These findings highlight the close relationship between the extent and severity of eczema and the intensity of itch experienced by patients and suggest that factors beyond the measured serum biomarkers play a significant role in the clinical manifestations of AD, emphasizing the complex nature of the disease.

Background: Pemphigus, an autoimmune blistering disease that affects the skin and mucous membranes, significantly impairs the quality of life (QoL) of affected individuals. While there are a variety of QoL measurement tools available for assessing this disease, there is a lack of studies that specifically evaluate the sexual QoL of patients with pemphigus.Objectives: This case–control study aims to investigate the impact of the disease on sexual activity as well as its overall effect on QoL.Materials and Methods: Fifty pemphigus patients, who were referred to the Dermatology Department at the University Hospital of Brescia in the period March 2019–September 2021, completed several QoL surveys, including the 36‐item Short Form Health survey (SF‐36), the 12‐Item General Health Questionnaire (GHQ‐12), the Autoimmune Bullous Disease Quality of Life (ABQOL) and either the International Index of Erectile Function (IIEF) or the Female Sexual Function Index (FSFI). The severity of the disease was assessed using the Pemphigus Disease Area Index (PDAI). Differences in QoL surveys between the case and control groups were analysed using either the t‐test or the Wilcoxon–Mann–Whitney test. The correlation between QoL surveys in pemphigus patients and disease severity were analysed using Spearman's coefficient (r).Results: The results revealed a marked impairment in overall QoL among patients with pemphigus compared to the healthy control subjects. Significant differences were observed in various domains of QoL, including physical health, mental well‐being, social functioning and, notably, sexual health.Furthermore, disease severity as evaluated by the PDAI showed correlations with specific aspects of health status, and disease‐specific QoL demonstrated associations with nearly all domains of health status. No significant correlations were found between sexual activity, mucosal involvement or steroid therapy and PDAI scores or disease‐specific QoL measures.Conclusion: These findings emphasize the significant impact of pemphigus on patients' well‐being, with particular attention to the impaired sexual activity.

Purpose: This prospective, single-center, open-label study aimed to evaluate the efficacy and safety of 1470 nm non-ablative laser therapy in treating facial acne scars. The primary objective was to assess improvements in skin texture, elasticity, and scar depth and diameter, while confirming the absence of significant adverse effects. Patients and Methods: 40 healthy female volunteers aged 18 to 42 years with facial acne scars underwent three sessions of 1470 nm laser therapy at two-week intervals. Outcome measures included cutometric assessments, high-frequency ultrasound evaluations, and clinical photographic documentation, conducted at baseline and on days 21, 42, 70, and 130 post-treatment. Results: Significant improvements were observed across all evaluated parameters. Skin elasticity increased progressively from baseline (mean: 62.95, SD=4.0) to day 21 (63.72, SD=3.8, +4%), day 42 (67.11, SD=4.0, +6%), day 70 (69.08, SD=4.2, +11%), and day 130 (70.80, SD=4.4, +14%; p< 0.001). High-frequency ultrasound measurements revealed substantial reductions in scar depth, which decreased by 5% at day 21 (mean: 0.18 mm, SD=0.05, p< 0.001), 20% at day 42 (0.15 mm, SD=0.055, p< 0.001), 48% at day 70 (0.10 mm, SD=0.06, p< 0.001), and 63% at day 130 (0.07 mm, SD=0.065, p< 0.001). Scar diameter followed a similar trend, with reductions of 16% at day 21 (3.08 mm, SD=0.3, p< 0.001), 26% at day 42 (2.71 mm, SD=0.34, p< 0.001), 42% at day 70 (2.13 mm, SD=0.36, p< 0.001), and 62% at day 130 (1.39 mm, SD=0.38, p< 0.001). Clinical photographic evaluations corroborated these quantitative findings, showing visible improvements in scar appearance and overall skin texture. No adverse events were reported throughout the study. Conclusion: The 1470 nm non-ablative laser therapy demonstrated high efficacy and safety in the treatment of acne scars, delivering substantial therapeutic benefits and high patient satisfaction, offering a valuable therapeutic option for addressing both pigmentation and textural issues associated with acne scars.